WO2005082348A3 - Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism - Google Patents

Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism Download PDF

Info

Publication number
WO2005082348A3
WO2005082348A3 PCT/US2005/006128 US2005006128W WO2005082348A3 WO 2005082348 A3 WO2005082348 A3 WO 2005082348A3 US 2005006128 W US2005006128 W US 2005006128W WO 2005082348 A3 WO2005082348 A3 WO 2005082348A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
present
dipeptidylpeptidase
glucose metabolism
regulating glucose
Prior art date
Application number
PCT/US2005/006128
Other languages
French (fr)
Other versions
WO2005082348A2 (en
Inventor
William W Bachovchin
Hung-Sen Lai
Wengen Wu
Original Assignee
Tufts College
William W Bachovchin
Hung-Sen Lai
Wengen Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2006133899/04A priority Critical patent/RU2379315C2/en
Priority to JP2007501012A priority patent/JP4781347B2/en
Priority to AU2005216970A priority patent/AU2005216970B2/en
Priority to BRPI0507972-1A priority patent/BRPI0507972A/en
Application filed by Tufts College, William W Bachovchin, Hung-Sen Lai, Wengen Wu filed Critical Tufts College
Priority to EP05723831A priority patent/EP1729757A2/en
Priority to KR1020137002340A priority patent/KR20130016435A/en
Priority to CA002558106A priority patent/CA2558106A1/en
Priority to KR1020067019660A priority patent/KR101292707B1/en
Priority to CN200580011588XA priority patent/CN1942182B/en
Priority to MXPA06009589A priority patent/MXPA06009589A/en
Publication of WO2005082348A2 publication Critical patent/WO2005082348A2/en
Publication of WO2005082348A3 publication Critical patent/WO2005082348A3/en
Priority to IL177644A priority patent/IL177644A0/en
Priority to NO20064307A priority patent/NO20064307L/en
Priority to IL217853A priority patent/IL217853A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Abstract

The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods of using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor that contain a carboxylic acid moiety. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.
PCT/US2005/006128 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism WO2005082348A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020137002340A KR20130016435A (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv
AU2005216970A AU2005216970B2 (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
BRPI0507972-1A BRPI0507972A (en) 2004-02-23 2005-02-23 compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition
KR1020067019660A KR101292707B1 (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv
EP05723831A EP1729757A2 (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
JP2007501012A JP4781347B2 (en) 2004-02-23 2005-02-23 Peptidyl peptidase IV inhibitors for controlling glucose metabolism
CA002558106A CA2558106A1 (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
RU2006133899/04A RU2379315C2 (en) 2004-02-23 2005-02-23 Dipeptidyl peptidase iv inhibitors
CN200580011588XA CN1942182B (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
MXPA06009589A MXPA06009589A (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism.
IL177644A IL177644A0 (en) 2004-02-23 2006-08-22 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
NO20064307A NO20064307L (en) 2004-02-23 2006-09-22 Inhibitors of dipeptidyl peptidase IV for the regulation of glucose metabolism
IL217853A IL217853A0 (en) 2004-02-23 2012-01-31 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54722704P 2004-02-23 2004-02-23
US60/547,227 2004-02-23
US59933604P 2004-08-06 2004-08-06
US60/599,336 2004-08-06

Publications (2)

Publication Number Publication Date
WO2005082348A2 WO2005082348A2 (en) 2005-09-09
WO2005082348A3 true WO2005082348A3 (en) 2005-12-29

Family

ID=34915595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006128 WO2005082348A2 (en) 2004-02-23 2005-02-23 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism

Country Status (13)

Country Link
US (4) US20050203027A1 (en)
EP (1) EP1729757A2 (en)
JP (1) JP4781347B2 (en)
KR (2) KR20130016435A (en)
AU (1) AU2005216970B2 (en)
BR (1) BRPI0507972A (en)
CA (1) CA2558106A1 (en)
IL (2) IL177644A0 (en)
MX (1) MXPA06009589A (en)
NO (1) NO20064307L (en)
RU (1) RU2379315C2 (en)
TW (1) TWI382836B (en)
WO (1) WO2005082348A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019494B1 (en) * 1997-09-29 2007-03-21 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP2316470A3 (en) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
EP2769715A3 (en) * 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
CA2484551A1 (en) * 2002-04-30 2003-11-13 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
US20050203027A1 (en) * 2004-02-23 2005-09-15 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
WO2007078726A2 (en) * 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
US8268880B2 (en) * 2005-12-19 2012-09-18 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
US20100105629A1 (en) * 2007-03-23 2010-04-29 Bachovchin William W N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8513187B2 (en) 2009-02-27 2013-08-20 Trustees Of Tufts College Soft protease inhibitors, and pro-soft forms thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
CA2795513A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CN103221410B (en) 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and the treatment to relative obstacle
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
HUE060305T2 (en) 2011-08-30 2023-02-28 Tufts College Fap-activated proteasome inhibitors for treating solid tumors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014008374A2 (en) * 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
US9593148B2 (en) 2012-11-02 2017-03-14 Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts DPP8 and DPP9 peptide inhibitors
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN107750467A (en) * 2015-06-23 2018-03-02 瑞典爱立信有限公司 Multicast broadcast multimedia service in advance（MBMS）Bulletin
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP3472149B1 (en) 2016-06-21 2023-08-30 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
CN109906082A (en) 2016-09-07 2019-06-18 塔夫茨大学信托人 Use the combined therapy of immune DASH inhibitor and PGE2 antagonist
KR102534947B1 (en) * 2017-01-18 2023-05-23 프린시피아 바이오파마, 인코퍼레이티드 immunoproteasome inhibitors
CN110996951A (en) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 PPAR gamma agonists for the treatment of progressive supranuclear palsy
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2020005046A (en) 2017-11-16 2020-08-20 Principia Biopharma Inc Immunoproteasome inhibitors.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0223849A (en) * 1988-06-08 1990-01-26 Morishita Pharmaceut Co Ltd Peptide-containing nutrient transfusion solution composition
EP0374534A1 (en) * 1988-12-22 1990-06-27 Novo Nordisk A/S Quinoxaline compounds and their preparation and use
EP0457314A1 (en) * 1990-05-18 1991-11-21 Clintec Nutrition Company Nutrient compositions containing peptides
JPH03264525A (en) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc Amino acid infusion solution
WO1999021008A1 (en) * 1997-10-23 1999-04-29 Pharmaprint, Inc. Pharmaceutical grade garlic

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5462928A (en) * 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) * 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1019494B1 (en) * 1997-09-29 2007-03-21 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
EP2433623A1 (en) * 1998-02-02 2012-03-28 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
IL139247A0 (en) * 1998-05-04 2001-11-25 Point Therapeutics Inc Hematopoietic stimulation
KR100704814B1 (en) * 1998-06-05 2007-04-10 포인트 써러퓨틱스, 인크. Cyclic Boroproline Compounds
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
CZ20023234A3 (en) * 2000-03-31 2003-01-15 Probiodrug Ag Medicament against diabetes mellitus
JP2002023849A (en) * 2000-06-30 2002-01-25 Ishikawajima Harima Heavy Ind Co Ltd Method for positioning moving object
US6963010B2 (en) * 2001-01-08 2005-11-08 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
EP2769715A3 (en) * 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP2316470A3 (en) * 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
JP2003264525A (en) * 2002-03-11 2003-09-19 Alps Electric Co Ltd Ofdm receiver
EP1578362A4 (en) * 2002-07-09 2008-11-05 Point Therapeutics Inc Boroproline compound combination therapy
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7259234B2 (en) * 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1743676A1 (en) * 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
US20050203027A1 (en) * 2004-02-23 2005-09-15 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
TWI297341B (en) * 2005-09-13 2008-06-01 Univ Nat Taiwan Normal A copolymer which is used as a dispersing agent for titanate-based ceramic colloids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0223849A (en) * 1988-06-08 1990-01-26 Morishita Pharmaceut Co Ltd Peptide-containing nutrient transfusion solution composition
EP0374534A1 (en) * 1988-12-22 1990-06-27 Novo Nordisk A/S Quinoxaline compounds and their preparation and use
JPH03264525A (en) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc Amino acid infusion solution
EP0457314A1 (en) * 1990-05-18 1991-11-21 Clintec Nutrition Company Nutrient compositions containing peptides
WO1999021008A1 (en) * 1997-10-23 1999-04-29 Pharmaprint, Inc. Pharmaceutical grade garlic

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199010, Derwent World Patents Index; Class B05, AN 1990-071167, XP002336354 *
DATABASE WPI Section Ch Week 199202, Derwent World Patents Index; Class B05, AN 1992-013563, XP002336355 *
DE GREEF W J ET AL: "Evidence that the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in human serum may not be secreted by the pituitary gland.", THE JOURNAL OF ENDOCRINOLOGY. NOV 1997, vol. 155, no. 2, November 1997 (1997-11-01), pages 393 - 399, XP008049922, ISSN: 0022-0795 *
DIETZE GJ, RETT K, WICKLMAYR M, MEHNERT H. FACHKLINIK BUHLERHOHE UND DER FORSCHERGRUPPE HYPERTONIE UND DIABETES, BUHL, BRD.: "[ACE-inhibitors and glucose metabolism]", WIEN MED WOCHENSCHR. 1990, vol. 1-2, no. 140, 1990, pages 35 - 39, XP008050011 *
JHAMANDAS K ET AL: "Role of excitatory amino acids in antagonist-precipitated morphine and clonidine withdrawal", REGULATORY PEPTIDES 1994 NETHERLANDS, no. SUPPL. 1, 1994, pages S215 - S216, XP008049923, ISSN: 0167-0115 *
MELCHIRO J C ET AL: "IMMUNOREACTIVE BETA ENDORPHIN INCREASES AFTER AN ASPARTAME CHOCOLATE DRINK IN HEALTHY HUMAN SUBJECTS", PHYSIOLOGY AND BEHAVIOR, vol. 50, no. 5, 1991, pages 941 - 944, XP008049964, ISSN: 0031-9384 *
RYAN J W ET AL: "A radiochemical assay for aminopeptidase N.", ANALYTICAL BIOCHEMISTRY. APR 1993, vol. 210, no. 1, April 1993 (1993-04-01), pages 27 - 33, XP008054069, ISSN: 0003-2697 *
SIDOROWICZ W ET AL: "KININ CLEAVAGE BY HUMAN ERYTHROCYTES", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, vol. 17, no. 4, 1984, pages 383 - 391, XP002095026 *
STRIFFLER J S ET AL: "Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 47, no. 10, October 1998 (1998-10-01), pages 1199 - 1204, XP004538742, ISSN: 0026-0495 *
VELASQUEZ M T ET AL: "Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes", METABOLISM: CLINICAL AND EXPERIMENTAL 1998 UNITED STATES, vol. 47, no. 12 SUPPL. 1, 1998, pages 7 - 11, XP008013954, ISSN: 0026-0495 *
WONG ANGELA ET AL: "Binding of (3H)-SK and F 107260 and (3H)-SB 214857 to purified integrin alphaIIbbeta3: Evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 285, no. 1, April 1998 (1998-04-01), pages 228 - 235, XP008054065, ISSN: 0022-3565 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
EP1729757A2 (en) 2006-12-13
WO2005082348A2 (en) 2005-09-09
US20090062235A1 (en) 2009-03-05
TWI382836B (en) 2013-01-21
US20050203027A1 (en) 2005-09-15
IL217853A0 (en) 2012-03-29
NO20064307L (en) 2006-11-15
IL177644A0 (en) 2008-04-13
AU2005216970B2 (en) 2011-07-07
JP4781347B2 (en) 2011-09-28
MXPA06009589A (en) 2007-03-26
RU2379315C2 (en) 2010-01-20
US20110218142A1 (en) 2011-09-08
KR101292707B1 (en) 2013-08-02
BRPI0507972A (en) 2007-07-24
KR20070030181A (en) 2007-03-15
RU2006133899A (en) 2008-03-27
CA2558106A1 (en) 2005-09-09
JP2007523216A (en) 2007-08-16
US20140018545A1 (en) 2014-01-16
AU2005216970A1 (en) 2005-09-09
KR20130016435A (en) 2013-02-14
TW200538096A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005082348A3 (en) Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
WO2003045977A3 (en) Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
WO2007100374A3 (en) Soft protease inhibitors and pro-soft forms thereof
WO2005082849A8 (en) Lactams as conformationally constrained peptidomimetic inhibitors
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
GEP20094679B (en) Dipeptidyl peptidase inhibitors
WO2004069162A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004064778A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103276A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006039325A3 (en) Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2003000180A3 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2006127530A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006127287A3 (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
WO2003000181A3 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004050022A3 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2003002530A3 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
TNSN08367A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MY142423A (en) Substituted aminoacetyl pyrrolidine compounds which are dipeptidyl peptidase iv inhibitors, and pharmaceutical compositions containing them
WO2004037169A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003082817A3 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2558106

Country of ref document: CA

Ref document number: 177644

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009589

Country of ref document: MX

Ref document number: 2007501012

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3458/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005723831

Country of ref document: EP

Ref document number: 2005216970

Country of ref document: AU

Ref document number: 1020067019660

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006133899

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011588.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005216970

Country of ref document: AU

Date of ref document: 20050223

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005216970

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005723831

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067019660

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0507972

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 217853

Country of ref document: IL